Psyence Biomedical Ltd. Files Form 6-K for March 2024
Ticker: PBMWW · Form: 6-K · Filed: Mar 12, 2024 · CIK: 1985062
Sentiment: neutral
Topics: reporting, pharmaceuticals, sec-filing
TL;DR
Psyence Biomedical Ltd. filed a 6-K on March 6, 2024, reporting on its activities.
AI Summary
On March 6, 2024, Psyence Biomedical Ltd. announced the issuance of a press release. The company, incorporated in Ontario, Canada, is a pharmaceutical preparations company (SIC 2834) with its principal executive offices located at 121 Richmond Street West, Toronto, Ontario. This filing is a Form 6-K report for the month of March 2024.
Why It Matters
This filing indicates ongoing reporting and corporate activities for Psyence Biomedical Ltd., a company in the pharmaceutical sector.
Risk Assessment
Risk Level: low — This filing is a routine report and does not contain significant new financial or operational information that would inherently increase risk.
Key Numbers
- 001-41937 — SEC File Number (Identifies the company's filing history with the SEC)
Key Players & Entities
- Psyence Biomedical Ltd. (company) — Filer of the Form 6-K
- March 6, 2024 (date) — Date of press release announcement
- 121 Richmond Street West Penthouse Suite 1300 Toronto, Ontario M5H 2K1 (location) — Principal executive office address
- 2834 (industry_code) — Standard Industrial Classification for Pharmaceutical Preparations
FAQ
What is the primary purpose of this Form 6-K filing?
The Form 6-K is a report of a foreign private issuer pursuant to Rule 13a-16 or 15d-16 under the Securities Exchange Act of 1934, filed for the month of March 2024, announcing the issuance of a press release on March 6, 2024.
Where is Psyence Biomedical Ltd. headquartered?
Psyence Biomedical Ltd.'s principal executive offices are located at 121 Richmond Street West Penthouse Suite 1300, Toronto, Ontario M5H 2K1.
What industry does Psyence Biomedical Ltd. operate in?
Psyence Biomedical Ltd. operates in the Pharmaceutical Preparations industry, as indicated by its Standard Industrial Classification code 2834.
What is the SEC file number for Psyence Biomedical Ltd.?
The SEC file number for Psyence Biomedical Ltd. is 001-41937.
Does Psyence Biomedical Ltd. file annual reports under Form 20-F or 40-F?
The filing indicates that Psyence Biomedical Ltd. files annual reports under cover of Form 20-F.
Filing Stats: 324 words · 1 min read · ~1 pages · Grade level 9.9 · Accepted 2024-03-12 17:25:46
Filing Documents
- tm248653d1_6k.htm (6-K) — 11KB
- tm248653d1_ex99-1.htm (EX-99.1) — 16KB
- tm248653d1_ex99-2.htm (EX-99.2) — 18KB
- tm248653d1_ex99-3.htm (EX-99.3) — 59KB
- tm248653d1_ex99-3img01.jpg (GRAPHIC) — 127KB
- tm248653d1_ex99-3img02.jpg (GRAPHIC) — 297KB
- tm248653d1_ex99-3img03.jpg (GRAPHIC) — 210KB
- tm248653d1_ex99-3img04.jpg (GRAPHIC) — 300KB
- tm248653d1_ex99-3img05.jpg (GRAPHIC) — 85KB
- tm248653d1_ex99-3img06.jpg (GRAPHIC) — 117KB
- tm248653d1_ex99-3img07.jpg (GRAPHIC) — 90KB
- tm248653d1_ex99-3img08.jpg (GRAPHIC) — 174KB
- tm248653d1_ex99-3img09.jpg (GRAPHIC) — 150KB
- tm248653d1_ex99-3img10.jpg (GRAPHIC) — 130KB
- tm248653d1_ex99-3img11.jpg (GRAPHIC) — 121KB
- tm248653d1_ex99-3img12.jpg (GRAPHIC) — 167KB
- tm248653d1_ex99-3img13.jpg (GRAPHIC) — 152KB
- tm248653d1_ex99-3img14.jpg (GRAPHIC) — 79KB
- tm248653d1_ex99-3img15.jpg (GRAPHIC) — 116KB
- tm248653d1_ex99-3img16.jpg (GRAPHIC) — 107KB
- tm248653d1_ex99-3img17.jpg (GRAPHIC) — 192KB
- tm248653d1_ex99-3img18.jpg (GRAPHIC) — 130KB
- tm248653d1_ex99-3img19.jpg (GRAPHIC) — 130KB
- tm248653d1_ex99-3img20.jpg (GRAPHIC) — 69KB
- tm248653d1_ex99-3img21.jpg (GRAPHIC) — 172KB
- tm248653d1_ex99-3img22.jpg (GRAPHIC) — 138KB
- tm248653d1_ex99-3img23.jpg (GRAPHIC) — 220KB
- tm248653d1_ex99-3img24.jpg (GRAPHIC) — 86KB
- tm248653d1_ex99-3img25.jpg (GRAPHIC) — 175KB
- tm248653d1_ex99-3img26.jpg (GRAPHIC) — 129KB
- tm248653d1_ex99-3img27.jpg (GRAPHIC) — 117KB
- tm248653d1_ex99-2img01.jpg (GRAPHIC) — 10KB
- tm248653d1_ex99-2img02.jpg (GRAPHIC) — 8KB
- 0001104659-24-033543.txt ( ) — 5613KB
From the Filing
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 6-K REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 UNDER THE SECURITIES EXCHANGE ACT OF 1934 For the month of March 2024 Commission File Number: 001-41937 Psyence Biomedical Ltd. (Translation of registrant’s name into English) 121 Richmond Street West Penthouse Suite 1300 Toronto, Ontario M5H 2K1 (Address of principal executive office) Indicate by check mark whether the registrant files or will file annual reports under cover of Form 20-F or Form 40-F. Form 20-F Form 40-F Indicate by check mark if the registrant is submitting the Form 6-K in paper as permitted by Regulation S-T Rule 101(b)(1): Indicate by check mark if the registrant is submitting the Form 6-K in paper as permitted by Regulation S-T Rule 101(b)(7): Explanatory Note On March 6, 2024, Psyence Biomedical Ltd., a corporation organized under the laws of Ontario, Canada (the “ Company ”), issued a press release announcing that its wholly-owned subsidiary, Psyence Australia (Pty) Ltd, has received full approval from the Australian Health Research Ethics Committee (HREC) to initiate its planned Phase IIb study in Melbourne, Australia. A copy of the press release is furnished hereto as Exhibit 99.1. On March 12, 2024, the Company issued a shareholder letter recapping recent progress and outlining key future milestones. The Company also released its investor presentation, dated March 2024. Copies of the shareholder letter and investor presentation are furnished hereto as Exhibits 99.2 and 99.3, respectively. Exhibits Exhibit Number Description 99.1 Press Release, dated March 6, 2024. 99.2 Shareholder Letter, dated March 12, 2024. 99.3 Investor Presentation, dated March 2024. SIGNATURE Pursuant to the requirements of the Securities Exchange Act of 1934, as amended, the registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorized. Dated: March 12, 2024 Psyence Biomedical Ltd. By: /s/ Dr. Neil Maresky Name: Dr. Neil Maresky Title: Chief Executive Officer and Director